Skip to main content
Full access
Letter to the Editor
Published Online: 1 August 2002

Tardive Dyskinesia and Ziprasidone

Publication: American Journal of Psychiatry
To the Editor: Cases of tardive dyskinesia associated with atypical neuroleptic medications have been reported (1); however, we are not aware of any cases in which tardive dyskinesia has been associated with ziprasidone. Ziprasidone, a newer atypical neuroleptic, is a serotonin 5-HT2A, dopamine D2, and α1 inhibitor, with a greater affinity for the 5-HT2A receptors than for the D2 receptors. It is a benzothiazolylpiperazine, structurally dissimilar to other antipsychotics, and is the only atypical antipsychotic that is an agonist at 5-HT1A receptor sites, an antagonist at 5-HT1D receptor sites, and an inhibitor of both norepinephrine and serotonin reuptake. Ziprasidone is indicated for the treatment of schizophrenia and schizoaffective disorder by the Food and Drug Administration, but several studies have suggested its effectiveness in the treatment of acute mania and bipolar disorder (2).
We report the case of a patient with bipolar disorder who had a history of tardive dyskinesia with typical neuroleptics. His symptoms had been latent for many years, including during a period of treatment with risperidone, but they reemerged with ziprasidone treatment.
Mr. A was a 49-year-old man with bipolar disorder type I who suffered from continued mild to moderate chronic bipolar depression. He had been diagnosed with bipolar disorder over 12 years ago and had previously been treated with lithium, lamotrigine, carbamazepine, amitriptyline, desipramine, fluoxetine, paroxetine, citalopram, and oxcarbazepine. Mr. A also had a history of long-term treatment with traditional antipsychotics. During a 20-year period of treatment with thiothixene, Mr. A developed mild tardive dyskinesia. These symptoms disappeared when treatment was terminated and did not recur when he started to take risperidone. Mr. A took risperidone for 2 years but did not develop tardive dyskinesia.
Mr. A’s medication regimen had been stable for several months and included lithium, clonazepam, ziprasidone, citalopram, and buspirone. Four months after Mr. A started taking ziprasidone, 100 mg/day, he began to experience symptoms of tardive dyskinesia again. Mr. A had seven consistently abnormal ratings of moderate to marked severity on the Abnormal Involuntary Movement Scale (AIMS) (3) over a period of 2 months. He experienced moderate improvement in depression but continued to have symptoms of tardive dyskinesia after 7 months of treatment with ziprasidone.
This case suggests that ziprasidone may be associated with the reemergence of tardive dyskinesia, particularly in a patient with several indicated risks, including long-term exposure to traditional neuroleptics and a diagnosis of bipolar disorder.

References

1.
Ghaemi SN, Ko JY: Quetiapine-related tardive dyskinesia (letter). Am J Psychiatry 2001; 158:1737
2.
McElroy SL, Keck PE Jr: Pharmacologic agents for the treatment of acute bipolar mania. Biol Psychiatry 2000; 48:539-557
3.
Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534-537

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1436
PubMed: 12153846

History

Published online: 1 August 2002
Published in print: August 2002

Authors

Details

KLARA J. ROSENQUIST, B.S.
S. NASSIR GHAEMI, M.D.
Cambridge, Mass.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share